Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103^intCD11b⁺ dendritic cell population.

ABSTRACT: Locoregional monotherapy with heterodimeric interleukin (IL)-15 (hetIL-15) in a triple-negative breast cancer (TNBC) orthotopic mouse model resulted in tumor eradication in 40% of treated mice, reduction of metastasis, and induction of immunological memory against breast cancer cells. hetIL-15 re-shaped the tumor microenvironment by promoting the intratumoral accumulation of cytotoxic lymphocytes, conventional type 1 dendritic cells (cDC1s), and a dendritic cell (DC) population expressing both CD103 and CD11b markers. These CD103^intCD11b⁺DCs share phenotypic and gene expression characteristics with both cDC1s and cDC2s, have transcriptomic profiles more similar to monocyte-derived DCs (moDCs), and correlate with tumor regression. Therefore, hetIL-15, a cytokine directly affecting lymphocytes and inducing cytotoxic cells, also has an indirect rapid and significant effect on the recruitment of myeloid cells, initiating a cascade for tumor elimination through innate and adoptive immune mechanisms. The intratumoral CD103^intCD11b⁺DC population induced by hetIL-15 may be targeted for the development of additional cancer immunotherapy approaches.

SUBMITTER: Stellas D 

PROVIDER: S-EPMC10758290 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature